ARTICLE | Company News
Verastem grants CSPC rights to Copiktra in China
September 28, 2018 5:38 PM UTC
Verastem Inc. (NASDAQ:VSTM) granted CSPC Pharmaceutical Group Ltd. (HKSE:1093) exclusive rights to develop and commercialize cancer drug Copiktra duvelisib in China, including Hong Kong and Macau, and Taiwan. The partners announced the deal on Sept. 25.
On Sept. 24, Copiktra became the first dual phosphoinositide-3-kinase (PI3K) δ and γ inhibitor to gain FDA approval, according to Verastem (see "FDA Approves Verastem's Duvelisib")...